Dose-escalation studies have been performed to find the optimal dose of Alpha1H for future therapeutic studies. In the murine bladder cancer model, we observed a strong protective effect, with a reduction in tumor size at moderate drug concentrations.
Higher concentrations even removed the tumor, with a clear dose-dependent treatment effect. These exiting findings are being analyzed further, using high-profile molecular techniques.
Importantly, there were no detected side effects or toxicity of this treatment even at the highest dose.
These findings open up novel possibilities to adjust the dose of Alpha1H to specific tumors and tissue sites and to develop tailored treatment protocols, to fit individual patients
For more information, contact
Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
Hamlet Pharma company listed on AktieTorget, is a company engaged in drug development based on a tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. The development aims to develop drugs that primarily will be used for the treatment and prevention of cancer. HAMLET effectively kills tumor cells but have also proven to be safe in the proof-of-concept studies done on humans. The substance has demonstrated therapeutic effect on skin papillomas in a placebo-controlled clinical trial and causes shedding of dead cancer cells by injection into the bladder in patients with bladder cancer. Hamlet Pharma intends to initiate a phase II study with Alpha1H in patients with bladder cancer, a difficult and costly cancer form. HAMLET is a registered trademark of Hamlet Pharma.